Skip to main content

Table 2 Secondary structure compositions of native and pegylated rhArg1 estimated by using CD analysis software.

From: Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)

  Native rhArg1 rhArg1-peg5,000 mw Native rat liver arginase
α-Helix 25% 24% 22%
β-Sheet 27% 28% 28%
Turns 13% 17% 17%
Random structure 36% 32% 33%